BioMarin Pharma (BMRN) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.90 +2.21%
Revenue Growth %: +13.2%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $505.3 million versus the consensus estimate of $516.56 million.
GUIDANCE:
BioMarin Pharma sees 2022 revenue of $2.06-2.16 billion, versus the consensus of $2.12 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
